Company / EPS (Diluted)
Innoviva, Inc. EPS (Diluted) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
$2.20
FY2025
5-year range
$1.43 / $2.87
FY2021-FY2025
Trend
-7.2%
vs FY2024
Sector context
#23 of 204
Health Care
What the data says
Innoviva, Inc.'s eps (diluted) of $2.20 is higher than 89% of companies in the Health Care sector (FY2025). EPS (Diluted) has fluctuated over the past 10 years, ranging from $-1.50 in FY2016 to $3.53 in FY2020.
Based on SEC 10-K filings.
2.20 in FY2025 with a 5-year CAGR of -9.0%. Top quartile in the Health Care sector.
Declined from $2.87 to $2.20 over the past 2 years.
Health Care sector context is included.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- +2.9%
- 5-Year CAGR
- -9.0%
- 10-Year CAGR
- -
Sector benchmark
Top 11% in Health CareTop 11% of 204This company $2.20 Sector average -$0.98
▼
+324.6% above sector average
Key checks
Key Insights
- In FY2025, eps (diluted) decreased 7.2% year-over-year.
- Ranks #23 out of 204 companies in the Health Care sector.
- Peak eps (diluted) was recorded in FY2020.
- Lowest eps (diluted) in the period was in FY2016.
Company context
Key Data Points
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $2.20 | -7.2% |
| FY2024 | $2.37 | -17.4% |
| FY2023 | $2.87 | +42.1% |
| FY2022 | $2.02 | +41.3% |
| FY2021 | $1.43 | -59.5% |
| FY2020 | $3.53 | +201.7% |
| FY2019 | $1.17 | +120.8% |
| FY2018 | $0.53 | +431.3% |
| FY2017 | -$0.16 | +89.3% |
| FY2016 | -$1.50 | +10.2% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026